Human peripheral blood lymphocytes (PBLs) electroporated with RNA encoding anti-Her-2/neu-specific chimeric immune receptor (CIR) have been reported to elicit potent immune responses against SKOV3 tumors in a nude mouse model. However, CIRelectroporated PBL (CIR-PBL) did not proliferate, and the cell number rapidly decreased in the absence of exogenous interleukin-2 (IL-2). In this study, PBLs electroporated with both CIR and IL-2 RNA (CIR/IL-2-PBL) were studied to determine whether antitumor effects could be improved by adoptive immunotherapy. CIR and IL-2 were expressed in CIR/IL-2-PBL at levels similar to PBLs electroporated, with IL-2 RNA (IL-2-PBL) or CIR-PBL. Transfer of IL-2 RNA induced proliferation and prolonged survival of PBLs in vitro. In a xenograft model, both IL-2-PBL and CIR/IL-2-PBL showed significantly higher antitumor effects than CIR-PBL. The number of tumor-infiltrating natural killer (NK) cells was significantly increased in IL-2-PBL and CIR/IL-2-PBL. After NK cell depletion, IL-2-PBL showed significantly lower antitumor effects than CIR/IL-2-PBL. These results suggest that transfer of IL-2 RNA to CIR-PBL can promote NK cell infiltration of tumors and prolong survival of infused PBLs in vivo. RNA electroporated PBLs may represent efficient tools for delivery of functional molecules to tumors by multiple gene transfer.
Introduction
The potential for infusion of lymphocytes, a technique referred to as adoptive immunotherapy, to provide successful treatment of cancer and chronic infections is currently being studied. Adoptive immunotherapy has the potential to enhance antitumor immunity and augment vaccine efficacy. 1 Tumor-infiltrating lymphocytes and cytotoxic T lymphocytes cultured from peripheral blood lymphocytes (PBLs) have been used to treat patients with refractory cancer.
1,2 Epstein-Barr virus-related lymphoma can be targeted using long-term-cultured Epstein-Barr virus-specific cytotoxic T lymphocytes, which were shown to persist up to 3 years in patients. 3, 4 However, T cells reactive against tumor antigens cannot be generated in every case, due to individual antigen variation as well as to variation in the priming capacity of antigen-presenting cells. 5 The peripheral T-cell repertoire is usually without high-avidity tumor-specific cytotoxic T lymphocytes due to thymic selection. 6 Moreover, tumor-specific cytotoxic T lymphocytes are often anergic or show a limited life span. 3, 7 Even if T cells with high avidity for antigens are generated, adoptive immunotherapy cannot be guaranteed to be successful because of the uncertainty of its persistency and reactivity in vivo. 5 Transgenic expression of T-cell receptor and chimeric immune receptors (CIR) aims to circumvent these constraints. 8 CIR genes that contain the coding sequence of an antibody-derived single-chain Fv directed against a tumor-associated antigen, connected to the transmembrane and intracytoplasmic sequences of T-cell signaling molecules, have been generated. 9 Subsequent transfection of these genes into cytotoxic T cells provides them the ability to specifically recognize and kill tumor cells. 10, 11 To improve the effectiveness of adoptive immunotherapy, we can use the infusion of interleukin-2 (IL-2) to activate host antigen-presenting cells with toll-like receptor agonists and stimulate the transferred cells in vivo, thus increasing their function and persistence. 12 IL-2 is a potent cytokine with a wide range of target immune cells; the interaction of IL-2 with its receptor stimulates the growth, differentiation and survival of antigen-selected T cells and natural killer (NK) cells. [13] [14] [15] [16] In cancer therapy, treatment with IL-2 was originally introduced as a systemic therapy and resulted in about a 20% responses rate. 17 Unfortunately, standard high-dose IL-2 therapy is associated with toxicity, due in part to a vascular leak syndrome; it can lead to renal and hepatic dysfunction, nausea, vomiting and thrombocytopenia. 18, 19 Several different strategies for targeting the immunostimulatory activity of the cytokine to the tumor site and thereby decreasing the systemic toxic side effects of IL-2 have been investigated. Adoptive immunotherapy for patients with melanoma was performed using tumorinfiltrating lymphocytes genetically engineered to secrete IL-2. 20 Intratumoral treatment with IL-2 is more effective than peritumoral treatment 17, 21 or treatment at a more distant site. 22 Peripheral blood lymphocytes or cytokine-induced killer cells electroporated with RNA encoding anti-Her-2/ neu-specific CIR have been shown to elicit potent immune responses against Her-2/neu-overexpressing SKOV3 tumors. 9, 23 The main problem with this approach has been that, due to lack of survival and gradual decrease in cell number, the antitumor effects of PBLs were not maintained long enough to target the tumors. In this study, we co-transfected dual RNAs encoding CIR and IL-2 to induce antigen-specific PBLs as well as maintain their activity by means of secretion of the survival factor in the physical location of the cells. Survival of the cells and specific responses against target antigen were observed in vitro and the antitumor effects of the cells were investigated using an SKOV3 xenograft model.
Materials and methods

Cells and antibodies
Human PBLs were grown in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM glutamine, penicillin (100 U ml À1 ) and streptomycin (10 mg ml À1 ) (Invitrogen, Gibco, Grand Island, NY). The human ovarian cancer cell line SKOV3, which expresses the Her-2/Neu antigen, was maintained in Dulbecco's modified Eagle's medium with the following additives: 10% (v/v) FBS, 2 mM glutamine, penicillin (100 U ml À1 ) and streptomycin (100 mg ml À1 ) (Invitrogen Gibco). The following mAbs were used in this study: 9E10 (mouse anti-cMyc FITC conjugated; Sigma, St Louis, MO), mouse anti-mouse Pan-NK (CD49b) PE-conjugated (eBioscience, San Diego, CA), anti-CD3 mAb (OKT3; Ortho Biotech Inc., Raritan, NJ).
In vitro transcription of messenger RNA The CIR containing anti-Her-2/neu scFv (single-chain variable fragment) joined to tag sequence for detection from c-myc region, the intracellular portion of CD28 and CD3z was kindly provided by Philip K Darcy (Peter MacCallum Cancer Centre, Australia). The CIR construction was subcloned into the pcDNA3.1 vector (Invitrogen) with the T7 promoter proximal to the start codon of the backbone. The pcDNA3.1-IL-2 is an expression vector combining human IL-2 cDNA. The in vitro transcription was performed with T7 RNA polymerase using the mMESSAGE mMACHINE T7 Ultra kit (Ambion Inc., Austin, TX) according to the manufacturer's instructions. After in vitro transcription, the mRNA was purified using phenol/chloroform (Sigma) and purified RNA was eluted in RNase-free water at 4-5 mg ml
À1
.
RNA electroporation of primary human PBLs
Transduction of human PBLs was performed as described previously. 24 Briefly, peripheral blood mononuclear cells from healthy donors were isolated by Ficoll-Paque density centrifugation (GE Healthcare Bio-Sciences, Uppsala, Sweden). PBLs were isolated from human peripheral blood mononuclear cells by depleting CD14 þ cells using microbeads (Miltenyi, Auburn, CA). CD14 À PBLs were activated with anti-CD3 (ORTHOCLONE OKT3, 500 ng ml
À1
; Ortho Biotech, Bridgewater, NJ) and recombinant human IL-2 (600 IU ml
; eBioscience) for 3 days. Stimulated PBLs were collected and resuspended at 1 Â 10 6 cells per 100 ml in OPTI-MEM (Invitrogen Gibco) containing mRNA. Cells were electroporated in 2-mm cuvettes at 400 V for 500 ms, using a square waveform generator (ECM 830 Electro Square Porator; BTX, a division of Genetronics, San Diego, CA). The electroporated PBLs were immediately transferred to medium containing 10% FBS cultured in 24-well tissue culture plates (2 ml per well). The next day, cell were harvested and used for flow cytometry analysis or functional assay. PBLs were grown in RPMI 1640 medium supplemented with 10% (v/v) FBS, 2 mM glutamine, penicillin (100 U ml
) and streptomycin (100 mg ml
; Invitrogen Gibco).
Cytokine measurement
Cytokine secretion by transduced PBLs on encountering target antigen was detected by enzyme-linked immunosorbent assay (eBioscience). Briefly, each of the RNAtransduced PBLs (1 Â 10 6 cells per ml) (CIR/IL-2-PBL, CIR-electroporated PBL (CIR-PBL), IL-2-PBL, mock-PBL) was incubated with Her-2/Neu-positive cells, SKOV3, in 48-well culture plates for 6 days at 37 1C. Each day, supernatants were collected and the levels of expression of IFN-g and IL-2 RNA were determined.
Evaluation of apoptosis
Apoptosis was detected by dual staining with FITCconjugated Annexin V and propidium iodide (PI; BD Pharmingen, San Diego, CA). Transduced PBLs were divided into 24 wells and cultured for 6 days. Each day, cells from one of the 24 wells were collected and stained for apoptosis.
CFSE labeling for in vivo tracking RNA-transduced PBLs were incubated with carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) at a final concentration of 5 mM for 10 min at 37 1C. The reaction was stopped by washing with ice-cold phosphate-buffered saline (PBS) supplemented with 10% FBS. CFSE-labeled RNA-transduced PBLs (2 Â 10 6 ) were administered into mice by intratumoral injection (Balb/c nu/nu; Orient Bio, Gyeonggi do, Korea). On a day after injection, the spleen and tumor were removed, minced and passed through a nylon mesh to yield a single-cell suspension. Erythrocytes were lysed by resuspending the cells in an ACK lysis buffer and immediately placing on ice for 10 min. The cells were washed with PBS and immediately fixed in paraformaldehyde (1% final concentration). The cells were detected by flow cytometry.
Nude mouse xenograft model and depletion of NK cells
Female athymic 4-week-old nude mice (Balb/c nu/nu; Orient Bio) were housed under specific pathogen-free conditions according to the guidelines of the animal care committee. All mice were ear-tagged and their individual tumor volumes were monitored during the experiment. After 1 week of acclimatization, mice were inoculated subcutaneously (26-gauge needle) with 1 Â 10 7 SKOV3 cells in a 0.4-ml single-cell suspension. After tumors become palpable, the antitumor efficacy of the intratumoral injection of 2 Â 10 6 PBLs expressing CIR and IL-2 was assessed and compared with that of CIR, IL-2 mock-PBLs and PBS. For depletion of NK cells, we intravenously administered 50 ml of antiasialo-GM1 antibody (Waco Pure Chemical Industries, Osaka, Japan) 6 days before tumor cell injection and once weekly thereafter, for a total of four injections. The treatments were performed thrice at 5-day intervals and mice were monitored daily for tumor growth. Following treatment, the tumor volume (mm 3 ) was estimated in accordance with the formula (tumor width 2 (mm) Â tumor length (mm)/2). All animals were handled according to the local and national regulations, and the local ethics committee approved the protocol.
Statistics
Statistical analysis was performed using the two-tailed Student's t-test for cytokine assay and the two-tailed Mann-Whitney nonparametric test for tumor volume measurement.
Results
Expression and function of CIR and IL-2
After 3 days of stimulation with OKT3 and IL-2, we electroporated human PBLs were RNA encoding CIR and/or IL-2 against Her-2/neu antigen. CIR was highly expressed in more than 98% of cells electroporated with CIR RNA or with CIR and IL-2 (CIR/IL-2) RNA on day 1 (Figure 1a ). There was no expression of CIR in mock-PBL or in IL-2-PBL. We also tested the kinetics of CIR expression with CIR/IL-2-PBL (Figure 1b) . Electroporation with 10 mg of RNA resulted in mean fluorescence intensity of about 76.9 on day 1. On day 2, the expression intensity was decreased to about one-third. On day 3, the mean fluorescence intensity decreased again to one-third of that observed the day before. After day 3, the mean fluorescence intensity remained at about 6-9 until day 6. IL-2-PBL and CIR/IL-2-PBL highly expressed IL-2 (25.7 ± 1.7 and 24.8 ± 2.8 ng ml À1 , **P ¼ 0.28) on day 1 after electroporation ( Figure 1c ). There was very low secretion of IL-2 in mock-PBL and CIR-PBL. Figure 1d shows IL-2 secretion by CIR/IL-2-PBL. A high level of IL-2 production (24.8 ± 2.8 ng ml À1 ) occurred on day 1. As observed by flow cytometry for CIR expression, secretion potency of IL-2 gradually decreased until day 6 (1.4 ± 0.5 ng ml
À1
). To define the antigen-specific response of CIR to Her-2/neu, we measured IFN-g production on day 1 on stimulation with SKOV3 cells (Figure 1e ). CIR-PBL and CIR/IL-2-PBL showed higher expression of IFN-g (52.8±2.4 and 73.8±5.4 ng ml
) than did mock-PBL (8.8±1.6 ng ml ). These results show that, after RNA electroporation into activated PBLs, both CIR and IL-2 were successfully expressed and functionally active.
Prolonged survival of PBL by transfer of IL-2 RNA After RNA electroporation, the number of PBLs in culture did not differ significantly among group until day 2. The number of mock-PBL and CIR-PBL cells remained similar to the number present immediately after electroporation, whereas the number of IL-2-PBL and CIR/ IL-2-PBL increased gradually after day 2 (6.5-and 7-fold at day 5, respectively; Figure 2a ). In the apoptosis assay using Annexin V and PI staining (Figure 2b ), the percentage of apoptotic cells in mock-PBL and CIR-PBL gradually increased from about 21% on day 0 to more than 65% after day 5. However, the percentage of apoptotic IL-2-PBL and CIR/IL-2-PBL did not increase at all. The effects of IL-2 RNA transfer were similar to those observed when exogenous IL-2 was added in culture (data not shown). These results suggest that transfer of IL-2 RNA can induce proliferation and prolong survival of activated PBLs while inhibiting apoptosis.
Migration of infused PBLs
To investigate the localization of intratumorally administrated PBLs, we analyzed CFSE-labeled cells in the spleen and tumor by flow cytometry (Figure 3) . On day 1 after infusion, 6.56, 4.84, 4 and 3.33% CFSE-positive cells, respectively, were detected inside tumor tissue for CIR/IL-2-PBL, CIR-PBL, IL-2-PBL and mock-PBL. The frequency of CFSE þ cells in spleen was much lower than in tumor, with CIR/IL-2-PBL showing a slight increase compared with the other groups. These results suggest that trapping of infused PBLs in the tumor site by CIR is further enhanced by IL-2.
Antitumor effects in nude mouse model A total of 1 Â 10 7 SKOV3 cells were subcutaneously injected into nude every 5 days for 15 days, at which time tumor volumes reached 50-100 mm 3 . Tumor-bearing mice that received CIR-PBL, IL-2-PBL or CIR/IL-2-PBL showed significantly slower tumor growth by day 30 after infusion than mice treated with PBS or mock-PBL (Figure 4) . Although tumors in mice treated with mock-PBL were smaller than those in the PBS control group mice, CIR/IL-2-PBL showed more inhibition of tumor growth than did mock-PBL (3.14-fold, **P ¼ 0.0068). Mice treated with CIR/IL-2-PBL or IL-2-PBL had smaller (2-, 1.7-fold) tumors compared with those of CIR-PBL (527 mm 3 ). Interestingly, IL-2-PBL-treated tumors showed similar inhibition to those that received CIR/IL-2-PBL (317 vs 263 mm 3 ; ****P ¼ 0.1230). These results show that transfer of IL-2 gene expression to CIR-PBL can enhance antitumor effects.
NK cell population in tumor and spleen
Because IL-2 is known to activate NK cells in addition to stimulating the proliferation of T cells, we measured the number of NK cells expressing a mouse Pan-NK marker, CD49b (DX5) in tumor site and spleen. The number of tumor-infiltrating NK cells was higher in the IL-2-PBLand CIR/IL-2-PBL-treated tumors (20.18 ± 1.71 and 20.31±2.7%) than in the other groups (Figure 5a ). Although the number of NK cells in spleen was slightly increased in IL-2-PBL-and CIR/IL-2-PBL-treated mice compared with the other groups, the increase was not significant (Figure 5b ). These results suggest that IL-2 secreted from infused PBLs shows paracrine effects localized to the tumor site rather than systemic effects.
Antitumor effects in NK cell depletion model
The strong inhibition of tumor growth by IL-2-PBL in vivo could be caused by activation of tumor-infiltrating Figure 1 Chimeric immune receptor (CIR) and IL-2 expression by RNA electroporation in activated human peripheral blood lymphocytes (PBLs). One day after electroporation, RNA-transduced PBLs (mock-PBL, IL-2-PBL, CIR-PBL and CIR/IL-2-PBL) were stained with FITCconjugated anti-cMyc monoclonal antibody (mAb) to examine CIR expression. The data are representative of three independent experiments (a). CIR expression with CIR/IL-2-PBL was measured each day following electroporation as indicated (solid line) and mock-transduced PBL (filled). The data are representative of three independent experiments (b). Supernatant from mock-PBL, IL-2-PBL, CIR-PBL and CIR/IL-2-PBL were harvested on after day 1 after electroporation and analyzed for IL-2 secretion by enzyme-linked immunosorbent assay (ELISA). *Po0.0003 when compared with CIR/IL-2-PBL; **P ¼ 0.28 when compared with CIR/IL-2-PBL (c). Supernatant from CIR/IL-2-PBL was measured for IL-2 secretion each day after electroporation (d). A total of 5 Â 10 5 mock-PBL, IL-2-PBL, CIR-PBL and CIR/IL-2-PBL were co-incubated with 5 Â 10 4 SKOV3 cells for antigen-specific stimulation. After 24 h of co-incubation, supernatants were collected and analyzed for IFN-g secretion by ELISA. ***Po0.0005 when compared with mock-PBL, IL-2-PBL and CIR-PBL (e). Error bars show ±s.e. from three experiments.
NK cells by IL-2 and IFN-g secreted from IL-2 transferred PBLs trapped in the tumor tissue. To test this hypothesis, we compared antitumor effects in the NKcell-depleted model compared with the non-depleted one ( Figure 6 ). In the NK-cell-non-depleted model, IL-2-PBL and CIR/IL-2-PBL had significantly higher antitumor effects than CIR-PBL (1.42-and 1.63-fold, respectively); IL-2-PBL and CIR/IL-2-PBL had similar effects on tumor volume (287.5 and 250.3 mm 3 , **P ¼ 0.14). However, in the NK depletion model, IL-2-PBL had significantly lower antitumor effects than CIR/IL-2-PBL (1.54-fold, **P ¼ 0.045) and was similar to CIR-PBL. After treatment with IL-2-PBL in the presence of NK cell depletion, tumor volume decreased significantly compared with treatment in the absence of NK cell depletion (***P ¼ 0.01); thus, as a result of NK cell depletion, the antitumor effects of IL-2-PBL were decreased to a level similar to that effected by CIR-PBL. These results suggest that transfer of IL-2 RNA to CIR-PBL can activate NK cells to infiltrate around the tumor as well as prolong the survival of infused PBL in vivo. 
Discussion
In early clinical trials, IL-2 therapy led to toxicity and to systemic inflammatory response syndrome, likely due to an inflammatory response mediated by the exogenously administered IL-2. 25 To avoid side effects caused by systemic administration, we deliver IL-2 locally by intratumoral injection of viral vectors. 26, 27 The covalent linkage of IL-2 and anti-CD3sFv protein was efficient in selectively protecting T cells from apoptotic cell death. 28 The fusion molecule of IL-2 and scFv binds to its target antigen in the tumor microenvironment and provides localized effector function by attracting cytotoxic immune cells. Insertion of the IL-2 gene into antitumor tumor-infiltrating lymphocytes by means of a retroviral vector also increased their ability to survival after IL-2 withdrawal in vitro. 20 In a clinical study, T cells retrovirally transduced with the IL-2 gene proliferated in the absence of exogenous IL-2 and could be actively grown and their survival could be maintained without added IL-2 for more than 8 weeks. 29 In this study, electroporation of IL-2 RNA also inhibited apoptosis and induced proliferation of PBLs in vitro and increased the number of PBLs trapped at the tumor site in vivo through the presence of an IL-2 autocrine loop. Conversely, IL-2 signaling pathways may be involved in maintaining peripheral tolerance by inducing activation-induced cell death, whereas IL-15 favors cell survival. 30, 31 It was also reported that both IL-2 and IL-15 could induce apoptosis and survival, with the outcome depending on cytokine concentration. 32 Other cytokines, such as IL-15 and IL-21, as well as co-stimulatory molecules such as 4-1BBL and CD80, have been reported to promote CD8 þ memory T-cell survival by pathways independent of the stimulation of regulatory T cells 33 and of effects on the human telomerase gene that counteract the loss of proliferative potential. 34 A number of reports from clinical studies that used scFv-engineered T cells have highlighted the efficacy of genetic modification of T cells, mostly mediated by retro-or lentivirus. 35, 36 Although a viral vector-based approach allows efficient transgene expression and generates stable transfectants through drug selection, the time and labor required for establishing transduced cell lines for vector production limits the efficacy of this method in clinical settings. In addition, there is a regulatory concern regarding the potential of viral insertional mutagenesis to cause cellular transformation. Thus, for practicality in clinical application, an alternative approach is required. [37] [38] [39] RNA electroporation initially was used to modify dendritic cells to express tumor antigens. 40, 41 Subsequently, RNA electroporation was used to transfer full-length TCR to T cells to confer upon them a new specificity. [42] [43] [44] Using this method, we previously showed that RNA-mediated gene transfer redirection of T-cell target antigens is an efficient nonviral gene transfer technology for T lymphocytes in terms of transduction efficiency and convenience in preparation. In this study, IL-2-PBL and CIR/IL-2-PBL highly expressed IL-2. Furthermore, the antigen-specific response of CIR to Her-2/neu was detected by stimulation with SKOV3 cells. These results show that both CIR and IL-2 were successfully expressed in activated PBLs by RNA electroporation and were functionally active.
We observed that IL-2-PBL, when stimulated with SKOV3 expressing Her-2/neu in vitro, secreted an intermediate level of IFN-g lower than that of CIR-PBL and CIR/IL-2-PBL. Because electroporated PBLs mainly included T and NK cells and allowed high efficiency of gene expression in CD4 þ , CD8 þ , CD56 þ T cells (495%), 9 IL-2 may further activate NK cells in response to SKOV3 to secrete IFN-g. 45 In a nude mouse xenograft model, CIR/IL-2-PBL showed enhanced infiltration of mouse NK cells by secreting IL-2 in addition to tumorspecific trapping by CIR. Because the number of NK cells in spleen was not significantly changed by IL-2-PBL or by CIR/IL-2-PBL, IL-2 secreted from infused PBLs may induce paracrine effects localized in the tumor site rather than systemic effects. Interestingly, tumors treated with IL-2-PBL showed more effective inhibition of tumor growth than those treated with CIR-PBL, whereas similar inhibition was observed in tumors treated with CIR/IL-2-PBL ( Figure 4 ). After depletion of NK cells, the inhibition of tumor growth by IL-2-PBL was decreased to a level similar to that caused by CIR-PBL. These results suggest that infiltration and activation of NK cells at the tumor site may be enhanced by IL-2 secreted from trapped IL-2-PBL. 46 Although high levels of CIR expression were observed in CD4 þ , CD8 þ and CD56 þ populations, the percentage of IFN-g-secreting cells in CIR-PBL on antigen stimulation with SKOV3 was 17% for CD8 þ , 3% for CD4 þ and 0.7% for CD56 þ cells, indicating that, even in the mixture of subsets, the response is mainly mediated by CD8 þ T cells. 9 Furthermore, the construct of CIR contains the signaling portions of CD28 and CD3z, which provide co-stimulatory signals and promotes secretion of additional type I cytokines, including IFN-g and TNF-a, in T cells. The absence of signaling domain from DAP12 may explain why NK cells expressing CIR were not as effective as CD8 þ T cells. Although these data suggest that transfected T cells exert their effects in a paracrine manner, the antitumor effects of this ill-defined system based on the bulk transfection of PBLs may also involve other mechanisms.
In a recent study showing specific and active antitumor effects with administration of modified human T cells in nude mice, 47 similar potent antitumor effects were observed following i.v. and intratumoral administration. However, further studies directly showing antitumor effects by i.v. administration of RNA transduced PBLs are required before the suitability of this method for clinical application can be considered. Because a xenograft nude mouse model was used to measure antitumor effects in this study, we could not measure the capacity of RNA transduced T cells to induce autoimmunity. Prominent autoimmunity resulting from this treatment might possibly be detected using a syngeneic mouse model. In addition, the role of regulatory T lymphocytes needs to be further defined. In this study, we showed that electroporation of both CIR and IL-2 RNA into PBLs Figure 6 Tumor growth in nude mice depleted of NK cell population. To eliminate NK activity in mice, 50 ml of antiasialo-GM1 antibody was administered intravenously 6 days before tumor cell injection and every week thereafter for a total of four injections. SKOV3 tumor cells (1 Â 10 7 ) were injected subcutaneously into the left flank of groups of six nude mice. Mice were treated three times with 2 Â 10 6 of RNA-transduced PBLs (IL-2-PBL, CIR-PBL, CIR/IL-2-PBL) at 5-day intervals. IL-2-PBL with control group inhibited tumor growth because NK cells were not depleted. *P ¼ 0.01 CIR/IL-2-PBL vs CIR-PBL; **P ¼ 0.14 for CIR/IL-2-PBL vs IL-2-PBL) (a). However, tumor growth in NK cell depleted mice was increased more than in the control group. (*P ¼ 0.038 for CIR/IL-2-PBL vs CIR-PBL; **P ¼ 0.045 for CIR/IL-2-PBL vs IL-2-PBL) (b). ***P ¼ 0.01 for IL-2-PBL in the presence of NK cell depletion vs IL-2-PBL in the absence of NK cell depletion. For all experiments, results are represented as the mean tumor volume (mm 3 ±s.e.m.).
could provide a valuable strategy of adoptive immunotherapy for the treatment of ovarian cancer. The adaptation of this approach to RNA electroporation of human PBLs may facilitate diverse trials using functional immune genes in addition to CIR to improve adoptive immunotherapy.
